

# **OPEN CALL**



**Abstract Selection  
Committee  
Member-  
Basic Science  
2016-2019**



**President Francisco X REAL**  
Epithelial Carcinogenesis Group  
Molecular Pathology Programme  
Centro Nacional de Investigaciones Oncológicas  
Melchor Fernández Almagro 3  
28029-Madrid  
Spain  
Tel: +34 917 328 000

**Secretary Peter HEGYI**  
First Department of Medicine  
Faculty of Medicine  
University of Szeged  
8-10 Koranyi fasor  
H-6720, Szeged  
Hungary  
Tel: +36-62-545200  
Fax: +36-62-545185

**Treasurer Rolf GRAF**  
Department of Surgery, Div. of  
Visceral & Transplant Surgery  
University Hospital  
Rämistrasse 100  
8091 Zurich  
Switzerland  
Tel: +41-44-2552071  
Fax: +41-44-2554449

## OPEN CALL

### For Abstract Selection Committee Members (representing Basic Science) at the European Pancreatic Club (EPC)

#### MINIMUM REQUIREMENTS

- Very good command of spoken and written English
- Personal commitment and time resources for volunteer work

#### ELIGIBILITY

- The applicant needs to be a member of the EPC during the term of abstract selection (2016-2019)
- The applicant has to be internationally acclaimed researcher
- The applicant has to have at least 2 communications (submitted abstracts, or poster, oral presentation or invited lectures) at the main or satellite EPC meetings (as a first or co-author)
- The applicant needs to assume to review the abstracts submitted for the EPC meeting within the given deadline
- The abstract scoring has to be fair and without bias
- Members of the Abstract Selection Committee are not allowed to score abstracts in which they are noted as author

#### TERMS OF OFFICE

- Members of the Abstract Selection Committee will be elected for 3 years (from January-January)
- Second term is not possible
- No parallel membership in EPC committees possible

#### SUBMITTING APPLICATIONS

Application has to be addressed to the Secretary of the EPC and must be in English.

Applications must include:

- filled application form (can be downloaded from the EPC webpage)
- CV

Applications will be filed and tagged by the Secretary of the EPC. Should the application prove deficient, the Applicant shall be notified at the e-mail address given by him/her within five working days. The Applicant then should eliminate the deficiency revealed within another five working days.

Arrival deadline for the submission: 5<sup>th</sup> June, 2015

Eligibility will be checked by the Council. Elections are performed at the General Assembly in the forthcoming EPC meeting in Toledo according to the rules stipulated in Article V in the statutes of the EPC.



**President Francisco X REAL**  
 Epithelial Carcinogenesis Group  
 Molecular Pathology Programme  
 Centro Nacional de Investigaciones Oncológicas  
 Melchor Fernández Almagro 3  
 28029-Madrid  
 Spain  
 Tel: +34 917 328 000

**Secretary Peter HEGYI**  
 First Department of Medicine  
 Faculty of Medicine  
 University of Szeged  
 8-10 Koranyi fasor  
 H-6720, Szeged  
 Hungary  
 Tel: +36-62-545200  
 Fax: +36-62-545185

**Treasurer Rolf GRAF**  
 Department of Surgery, Div. of  
 Visceral & Transplant Surgery  
 University Hospital  
 Rämistrasse 100  
 8091 Zurich  
 Switzerland  
 Tel: +41-44-2552071  
 Fax: +41-44-2554449

## APPLICATION FORM

for Abstract Selection Committee Member (representing Basic Science) of the European  
 Pancreatic Club (EPC)

1	<b>Personal data</b>	Name: Guillermet-Guibert Username ( <a href="http://www.e-p-c.org">www.e-p-c.org</a> ): Guillermet-Guibert ID 40366 Country: France National Society: French Pancreatic Club
2	<b>Membership</b>	List of years when the applicant was member of EPC (if applicable): - 2013  List of years when the applicant attended the annual EPC meeting (if applicable): - 2013  List of years when the applicant had communication(s) at the annual main or satellite EPC meeting: -2013 -2014
3	<b>Publications</b>	List of the best 5 original/review papers in international journals:  Baer R, Cintas C, Dufresne M, Planque L, Schönhuber N, Cassant-Sourdy S, Lulka H, Bousquet C, Garmy-Susini B, Vanhaesebroeck B, Pyronnet S, Saur D, <b>Guillermet-Guibert J.</b> The non-mutated p110 $\alpha$ PI 3-kinase is a master signaling enzyme in pancreatic cancerogenesis". <i>Genes &amp; Dev.</i> 2014 Dec 1;28(23):2621-35.  Vanhaesebroeck, B., <b>J. Guillermet-Guibert</b> , M. Graupera, and B. Bilanges, The emerging mechanisms of isoform-specific PI3K signalling. <i>Nat Rev Mol Cell Biol</i> , 2010. 11(5): p. 329-41.  <b>Guillermet-Guibert, J.</b> L. Davenne, D. Pchejetski, N. Saint-Laurent, L. Brizuela, C. Guilbeau-Frugier, M.B. Delisle, O. Cuvillier, C. Susini, and C. Bousquet, Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. <i>Mol Cancer Ther</i> , 2009. 8(4): p. 809-20.  Graupera, M., <b>J. Guillermet-Guibert</b> , L.C. Foukas, L.K. Phng, R.J. Cain, A. Salpekar, W. Pearce, S. Meek, J. Millan, P.R. Cutillas, A.J. Smith, A.J. Ridley, C. Ruhrberg, H. Gerhardt, and B. Vanhaesebroeck, Angiogenesis selectively requires the p110 $\alpha$ isoform of PI3K to control endothelial cell migration. <i>Nature</i> , 2008. 453(7195): p. 662-6.

		<b>Guillermet-Guibert, J.</b> , K. Bjorklof, A. Salpekar, C. Gonella, F. Ramadani, A. Bilancio, S. Meek, A.J. Smith, K. Okkenhaug, and B. Vanhaesebroeck, The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. <i>Proc Natl Acad Sci U S A</i> , 2008. 105(24): p. 8292-7.
4	<b>Previous positions at EPC or UEG</b>	NONE Junior member of COST Action N Malats BM1204 WP4

The applicant confirms that she/he

- has read the Open call for Abstract Selection Committee Member (Basic Science) position and fully accept its content
- has adequate time resources for volunteer work
- has good command of spoken and written English

Name

Julie Guillermet-Guibert

Date 15th of May 2015

**Curriculum Vitae****Dr. Julie Guillermet-Guibert** CR1 INSERM

Married, 2 Children

Group leader Team 17 « PI3K isoforms, Signalling &amp; Cancerogenesis"

CRCT, Toulouse, INSERM UMR1037/Université Paul Sabatier

2 avenue Hubert Curien; Oncopole de Toulouse; CS 53717; 31037 TOULOUSE CEDEX 1 - FRANCE

Tel. +33-(0) 5 82 74 16 52 [julie.guillermet@inserm.fr](mailto:julie.guillermet@inserm.fr)**ACADEMIC ACHIEVEMENTS**

---

May 2009 **Successful Competitive Examination** for a position in INSERM2001-2005 **PhD in Molecular and Cellular Biology and Pharmacology***Apoptotic effect of the somatostatin receptor sst2 in pancreatic cancer cells*

Université Paul Sabatier, Toulouse, France Supervisor: Dr Christiane Susini

Thesis on July the 13<sup>th</sup> 2005, *cum maxima laude*2000-2001 **Master in Molecular and Cellular Biology & Physiology** – Normalienne

Ecole Normale Supérieure de Lyon (ENSL), Lyon, France; With honours, Rank: 2/37

**DEA in Biology Health Biotechnologies: Pharmacological Innovation**

Université Paul Sabatier, Toulouse, France; With honours, Rank: 1/15

1996-98 **First University degree: Classe préparatoire BCPST Biology – Chemistry – Physics - Geology**

Lycée Henri IV, Paris, France

**CURRENT POSITION**

---

Dec 2013- now Team 17 in **CRCT INSERM U1037**- Toulouse- Dir JJ Fournié**SIGDYN- PI3K isoforms, Signalling & Cancerogenesis**<http://www.crct-inserm.fr/17-j-guillermet-guibert-sigdyn-group-pi3k-isoforms-signalling-cancerogenesis-559.html>

Collaborations

Pr. Vanhaesebroeck B (IOC, London)

Dr. Dufresne M (U1037, CRCT, Toulouse)

Pr. Saur D (Technical University, Munich)

**PREVIOUS**

---

March 2010-Dec 2013 **Junior Researcher (INSERM)***Role of PI3K isoforms in pancreatic cancer*

INSERM U1037, CRCT, Toulouse, France. Eq S Pyronnet Dir: Dr. Jean-Jacques

Fournié

Sept2005-Feb 2010 **Postdoctoral fellow** *Role of PI3Kbeta isoform in angiogenesis & in physiology*

Ludwig Institute for Cancer Research, London, UK. Dir: Prof. Xin Lu

IOC, Barts &amp; the London, UK. Dir: Prof. Nick Lemoine

Supervisor: Prof. Bart VANHAESEBROECK

Sept2001-Sept2005 **PhD** *Apoptotic effect of somatostatin receptor sst2 in pancreatic cancer cells*

INSERM Unit 531, Toulouse, France. Dir: Dr Lucien PRADAYROL

Supervisor: Dr. Christiane Susini

**PERSONAL GRANTS and FUNDINGS**

---

1998 **Ecole Normale Supérieure de Lyon ENSL Civil Servant Study Fellowship** (for 4 years)

after highly competitive National Entrance Examination

from the Education and Research Ministry of the French Government

2002 **Competitive PhD program** (for 3 years): **Allocation couplée pour Normalien**

from the Education and Research Ministry of the French Government

2005 **French Post-doctoral Fellowship**

from Fondation pour la Recherche Médicale (FRM)- French Charity

2006 **EMBO Post-doctoral Fellowship** (LTF)

- 2008 **Marie Curie Intra-European Fellowships for Career Development**  
(IEF-Framework 6 program)
- 2009 **Competitive Examination** for a position in INSERM
- 2011 **EU-ERG**

## AII PUBLICATIONS

---

Pubmed link:

<http://www.ncbi.nlm.nih.gov/gate2.inist.fr/pubmed/?term=guillermet-guibert+j+OR+guillermet+j>

1. Baer R, Cintas C, Dufresne M, Planque L, Schönhuber N, Cassant-Sourdy S, Lulka H, Bousquet C, Garmy-Susini B, Vanhaesebroeck B, Pyronnet S, Saur D, **Guillermet-Guibert J.** The non-mutated p110 $\alpha$  PI 3-kinase is a master signaling enzyme in pancreatic cancerogenesis". *Genes & Dev.* 2014 Dec 1;28(23):2621-35. [Top 5 most read G&D papers in the last 5 days](#)
2. Morfoisse, F., A. Kuchnio, C. Frainay, A. Gomez-Brouchet, M.B. Delisle, S. Marzi, A.C. Helfer, F. Hantelys, F. Pujol, **J. Guillermet-Guibert**, C. Bousquet, M. Dewerchin, S. Pyronnet, A.C. Prats, P. Carmeliet, and B. Garmy-Susini, Hypoxia Induces VEGF-C Expression in Metastatic Tumor Cells via a HIF-1 $\alpha$ -Independent Translation-Mediated Mechanism. *Cell Rep*, 2014. 6(1): p. 155-67.
3. Soler, A., H. Serra, W. Pearce, A. Angulo, **J. Guillermet-Guibert**, L.S. Friedman, F. Vinals, H. Gerhardt, O. Casanovas, M. Graupera, and B. Vanhaesebroeck, Inhibition of the p110 $\alpha$  isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis. *J Exp Med*, 2013. 210(10): p. 1937-45.
4. Baer, R., S. Pyronnet, and **J. Guillermet-Guibert**, Increase in PI3K signalling mimics mutated-Kras induction of pancreatic cancer. *Clin Res Hepatol Gastroenterol*, 2013. 37(4): p. 320-1.
5. Berenjano, I.M., **J. Guillermet-Guibert**, W. Pearce, A. Gray, S. Fleming, and B. Vanhaesebroeck, Both p110 $\alpha$  and p110 $\beta$  isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor. *Biochem J*, 2012. 442(1): p. 151-9.
6. Gratacap, M.P., **J. Guillermet-Guibert**, V. Martin, G. Chicanne, H. Tronchere, F. Gaits-Iacovoni, and B. Payrastre, Regulation and roles of PI3K $\beta$ , a major actor in platelet signaling and functions. *Adv Enzyme Regul*, 2011. 51(1): p. 106-16.
7. Vanhaesebroeck, B., **J. Guillermet-Guibert**, M. Graupera, and B. Bilanges, The emerging mechanisms of isoform-specific PI3K signalling. *Nat Rev Mol Cell Biol*, 2010. 11(5): p. 329-41. [305 citations](#)
8. Martin, V., **J. Guillermet-Guibert**, G. Chicanne, C. Cabou, M. Jandrot-Perrus, M. Plantavid, B. Vanhaesebroeck, B. Payrastre, and M.P. Gratacap, Deletion of the p110 $\beta$  isoform of phosphoinositide 3-kinase in platelets reveals its central role in Akt activation and thrombus formation in vitro and in vivo. *Blood*, 2010. 115(10): p. 2008-13.
9. **Guillermet-Guibert, J.**, L. Davenne, D. Pchejetski, N. Saint-Laurent, L. Brizuela, C. Guilbeau-Frugier, M.B. Delisle, O. Cuvillier, C. Susini, and C. Bousquet, Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. *Mol Cancer Ther*, 2009. 8(4): p. 809-20.
10. Al-Qassab, H., M.A. Smith, E.E. Irvine, **J. Guillermet-Guibert**, M. Claret, A.I. Choudhury, C. Selman, K. Piipari, M. Clements, S. Lingard, K. Chandarana, J.D. Bell, G.S. Barsh, A.J. Smith, R.L. Batterham, M.L. Ashford, B. Vanhaesebroeck, and D.J. Withers, Dominant role of the

p110beta isoform of PI3K over p110alpha in energy homeostasis regulation by POMC and AgRP neurons. *Cell Metab*, 2009. 10(5): p. 343-54.

11. **Guillermet-Guibert, J.**, K. Bjorklof, A. Salpekar, C. Gonella, F. Ramadani, A. Bilancio, S. Meek, A.J. Smith, K. Okkenhaug, and B. Vanhaesebroeck, The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. *Proc Natl Acad Sci U S A*, 2008. 105(24): p. 8292-7. [161 citations - Hot paper of the year ISI Web of knowledge](#)
13. Graupera, M., **J. Guillermet-Guibert**, L.C. Foukas, L.K. Phng, R.J. Cain, A. Salpekar, W. Pearce, S. Meek, J. Millan, P.R. Cutillas, A.J. Smith, A.J. Ridley, C. Ruhrberg, H. Gerhardt, and B. Vanhaesebroeck, Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. *Nature*, 2008. 453(7195): p. 662-6. [174 citations - Hot paper of the year ISI Web of knowledge](#)
14. **Guillermet, J.**, N. Saint-Laurent, P. Rochaix, O. Cuvillier, T. Levade, A.V. Schally, L. Pradayrol, L. Buscail, C. Susini, and C. Bousquet, *Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis*. *PNAS*, 2003. **100**(1): p. 155-160.
15. Bousquet\*, C., **J. Guillermet-Guibert\***, N. Saint-Laurent, E. Archer-Lahlou, F. Lopez, M. Fanjul, A. Ferrand, D. Fourmy, C. Pichereaux, B. Monsarrat, L. Pradayrol, J.-P. Esteve, and C. Susini, *Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway*. *EMBO Journal*, 2006. **25**(17): p. 3943-3954. **\*co-first authors**
16. **Guillermet-Guibert, J.**, N. Saint-Laurent, L. Davenne, P. Rochaix, O. Cuvillier, M.D. Culler, L. Pradayrol, L. Buscail, C. Susini, and C. Bousquet, *Novel synergistic mechanism for sst2 somatostatin and TNF alpha receptors to induce apoptosis: crosstalk between NF-kappa B and JNK pathways*. *Cell Death and Differentiation*, 2007. **14**(2): p. 197-208.
17. Chalabi M, Duluc C, Caron P, Vezzosi D, **Guillermet-Guibert J**, Pyronnet S, Bousquet C. Somatostatin analogs: does pharmacology impact antitumor efficacy? *Trends Endocrinol Metab*. 2014 Mar;25(3):115-27. doi: 10.1016/j.tem.2013.11.003. Epub 2014 Jan 7. Review.
18. Bousquet, C., **J. Guillermet**, F. Vernejoul, H. Lahlou, L. Buscail, and C. Susini, *Somatostatin receptors and regulation of cell proliferation*. *Digestive and Liver Disease*, 2004. **36**: p. S2-S7.
19. Lahlou, H., **J. Guillermet**, M. Hortala, F. Vernejoul, S. Pyronnet, C. Bousquet, and C. Susini, *Molecular signaling of somatostatin receptors*, in *Gastroenteropancreatic Neuroendocrine Tumor Disease: Molecular and Cell Biological Aspects*, B.C.G.M.H.M.R.J.C. Wiedenmann, Editor. 2004. p. 121-131.
20. Bousquet, C., **J. Guillermet**, N. Saint-Laurent, M. Fanjul, J.P. Esteve, S. Pyronnet, and C. Susini, *Antioncogenic role of somatostatin receptor subtype-2 in pancreatic cancer*. *European Journal of Endocrinology*, 2005. **152**.
21. **Guillermet-Guibert, J.**, H. Lahlou, P. Cordelier, C. Bousquet, S. Pyronnet, and C. Susini, *Physiology of somatostatin receptors*. *Journal of endocrinological investigation*, 2005. **28**(11 Suppl International): p. 5-9.
22. **Guillermet-Guibert, J.**, H. Lahlou, S. Pyronnet, C. Bousquet, and C. Susini, *Somatostatin receptors as tools for diagnosis and therapy: Molecular aspects*. *Best Practice & Research in Clinical Gastroenterology*, 2005. **19**(4): p. 535-551.



## INVITED SEMINARS

---

- **EMBL** (Host: Dr. Iain Mattaj), Somatostatin, Apoptosis & Pancreatic cancer, Heidelberg, Germany, June 2005.
- **Institute of Biochemistry and Genetics, University of Basel** (Host: Prof Gerhard Cristofori), Basel, Switzerland, October 2005.
- **Inserm U563** (Host: Dr. Bernard Payrastre) Centre de Physiopathologie de Toulouse Purpan (CPTP), Toulouse, France, 8 Feb 2008.
- **IFR31** (Host: Dr. Corinne Bousquet) Institut Louis Bugnard, Toulouse, France, 29 May 2008.
- **Technische Universität München** (Host: Dr Dieter Saur) Munich, Germany, 19 July 2010.
- **I2MC**, Toulouse, France, 12 April 2011.
- **Translational Seminar on Pancreatic cancer**, (Host : Cancéropole GSO), Montpellier, France, 26 May 2011.
- **Technische Universität München** (Host: Dr Dieter Saur) Munich, Germany, July 2014.

## PERSONAL AWARDS

---

- 2002 **Best Abstract Plenary Oral Session** DDW Digestive Disease Week, San Francisco  
2004 **Best Young Researcher** from the French National Society of Gastroenterology  
2014 **Nature Oral Prize + EMBO Travel award** EMBO Workshop, Bilbao

## MEMBERSHIP

---

EMBO Fellows since 2006  
COST program: Network on Pancreatic cancer in Europe since 2013  
CFP Club Français du Pancréas since 2000  
EPC European Pancreatic Club since 2012  
CECED Club des Cellules Epitheliales Digestives since 2000  
SFBBM Société Française de Biochimie et de Biologie Moléculaire since 2005